🇺🇸 Digoxin (0.25mg) in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 11

Most-reported reactions

1. Incorrect Dose Administered — 2 reports (18.18%)
2. Arrhythmia — 1 report (9.09%)
3. Asthenia — 1 report (9.09%)
4. Blister — 1 report (9.09%)
5. Bradycardia — 1 report (9.09%)
6. Cardioactive Drug Level Increased — 1 report (9.09%)
7. Chronic Obstructive Pulmonary Disease — 1 report (9.09%)
8. Condition Aggravated — 1 report (9.09%)
9. Death — 1 report (9.09%)
10. Disease Complication — 1 report (9.09%)

Source database →

Frequently asked questions

Is Digoxin (0.25mg) approved in United States?

Digoxin (0.25mg) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Digoxin (0.25mg) in United States?

Advenchen Laboratories, LLC is the originator. The local marketing authorisation holder may differ — check the official source linked above.